Decreased expression of Neurensin-2 correlates with poor prognosis in hepatocellular carcinoma

被引：19
作者：
Ma, Hai-Qing [1 ,2 ]
Liang, Xiao-Ting [1 ,2 ]
Zhao, Jing-Jing [1 ,2 ]
Wang, Hui [1 ,2 ]
Sun, Jian-Cong [1 ,2 ]
Chen, Yi-Bing [1 ,2 ]
Pan, Ke [1 ,2 ]
Xia, Jian-Chuan [1 ,2 ]
机构：
[1] Sun Yat Sen Univ, State Key Lab Oncol So China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Dept Expt Res, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2009年 / 15卷 / 38期
关键词：
Neurensin-2; Hepatocellular carcinoma; Expression; Immunohistochemical analysis; Prognosis; LIVER-CANCER; IN-VIVO;
D O I：
10.3748/wjg.15.4844
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
AIM: To investigate the expression of Neurensin-2 (NRSN2) in hepatocellular carcinoma (HCC) and its prognostic values in predicting survival. METHODS: The expression and prognostic significance of NRSN2 in HCC was examined by performing immunohistochemical analysis using a total of 110 HCC clinical tissue samples, and Western blotting analysis to further confirm the result. RESULTS: Decreased NRSN2 expression was shown in 70.9% cases. Loss of NRSN2 expression in HCC was significantly related to tumor size (P = 0.006). Larger tumor size was related to negative expression of NRSN2. Patients showing negative NRSN2 expression had a significantly shorter overall survival than those with positive expression (P = 0.008). Multivariate Cox regression analysis indicated that NRSN2 expression level was an independent factor of survival (P = 0.013). Western blotting analysis further confirmed decreased expression of NRSN2 in tumor tissues compared with non-tumorous tissues. CONCLUSION: Our study indicated that NRSN2 could be a tumor suppressor gene for HCC and a candidate biomarker for long-term survival in HCC. (C) 2009 The WIG Press and Baishideng. All rights reserved.
引用
收藏
页码：4844 / 4848
页数：5
相关论文
共 13 条
[1]   Molecular Mechanisms of Hepatocellular Carcinoma [J].
Aravalli, Rajagopal N. ;
Steer, Clifford J. ;
Cressman, Erik N. K. .
HEPATOLOGY, 2008, 48 (06) :2047-2063
[2]   Probing tumor phenotypes using stable and regulated synthetic microRNA precursors [J].
Dickins, RA ;
Hemann, MT ;
Zilfou, JT ;
Simpson, DR ;
Ibarra, I ;
Hannon, GJ ;
Lowe, SW .
NATURE GENETICS, 2005, 37 (11) :1289-1295
[3]   An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo [J].
Hemann, MT ;
Fridman, JS ;
Zilfou, JT ;
Hernando, E ;
Paddison, PJ ;
Cordon-Cardo, C ;
Hannon, GJ ;
Lowe, SW .
NATURE GENETICS, 2003, 33 (03) :396-400
[4]   Hepatocellular carcinoma [J].
Okuda, K .
JOURNAL OF HEPATOLOGY, 2000, 32 :225-237
[5]   Estimating the world cancer burden: GLOBOCAN 2000 [J].
Parkin, DM ;
Bray, F ;
Ferlay, J ;
Pisani, P .
INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (02) :153-156
[6]   Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma [J].
Poon, RTP ;
Fan, ST ;
Wong, J .
ANNALS OF SURGERY, 2000, 232 (01) :10-24
[7]   The prognostic molecular markers in hepatocellular carcinoma [J].
Qin, LX ;
Tang, ZY .
WORLD JOURNAL OF GASTROENTEROLOGY, 2002, 8 (03) :385-392
[8]   Hepatocellular carcinoma: Molecular pathways and new therapeutic targets [J].
Roberts, LR ;
Gores, GJ .
SEMINARS IN LIVER DISEASE, 2005, 25 (02) :212-225
[9]   Second-generation shRNA libraries covering the mouse and human genomes [J].
Silva, JM ;
Li, MZ ;
Chang, K ;
Ge, W ;
Golding, MC ;
Rickles, RJ ;
Siolas, D ;
Hu, G ;
Paddison, PJ ;
Schlabach, MR ;
Sheth, N ;
Bradshaw, J ;
Burchard, J ;
Kulkarni, A ;
Cavet, G ;
Sachidanandam, R ;
McCombie, WR ;
Cleary, MA ;
Elledge, SJ ;
Hannon, GJ .
NATURE GENETICS, 2005, 37 (11) :1281-1288
[10]   Genetics of hepatocellular carcinoma [J].
Teufel, Andreas ;
Staib, Frank ;
Kanzler, Stephan ;
Weinmann, Arndt ;
Schulze-Bergkamen, Henning ;
Galle, Peter R. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (16) :2271-2282
12